Impressive Response to Tandem Treatment With [90Y]DOTATOC and [177Lu]DOTATOC in Grade 3 Pancreatic Neuroendocrine Carcinoma

Alice Lorenzoni, Antonella Capozza, Salvatore Artale, Marco Maccauro, Ettore Cesare Seregni

Research output: Contribution to journalArticle


Peptide receptor radionuclide therapy is an effective, well-tolerated, treatment for well-differentiated neuroendocrine tumors, resulting in a significant survival benefit and improvement of quality of life. Very few data are available on peptide receptor radionuclide therapy effectiveness in grade 3 neuroendocrine carcinomas with high somatostatin receptor expression. We report the case of a 70-year-old woman with metastatic pancreatic grade 3 neuroendocrine carcinoma who underwent 6 cycles of tandem treatment with investigational radiopharmaceuticals Y-DOTATOC and Lu-DOTATOC achieving an impressive response.

Original languageEnglish
Pages (from-to)506-508
Number of pages3
JournalClinical Nuclear Medicine
Issue number7
Publication statusPublished - Jul 2018



  • Aged
  • Carcinoma, Neuroendocrine/diagnostic imaging
  • Female
  • Humans
  • Octreotide/analogs & derivatives
  • Pancreatic Neoplasms/diagnostic imaging
  • Radiopharmaceuticals/therapeutic use

Cite this